Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction

European Journal of Heart Failure

Volumn 13, Issue 2, 2011, Pages 148-153

  Thune, Jens Jakob ^a,b   Signorovitch, James E ^a   Kober, Lars ^b   McMurray, John J V ^c   Swedberg, Karl ^d   Rouleau, Jean ^e   Maggioni, Aldo ^f   Velazquez, Eric ^g   Califf, Robert ^g   Pfeffer, Marc A ^a   Solomon, Scott D ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Rigshospitalet   (Denmark)

^c WESTERN INFIRMARY   (United Kingdom)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

^f ANMCO RESEARCH CENTER   (Italy)

^g DUKE UNIVERSITY   (United States)

Author keywords

Epidemiology; Mortality; Myocardial infarction

Indexed keywords

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; DIABETES MELLITUS; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HAZARD RATIO; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENT MYOCARDIAL INFARCTION; SURVIVAL TIME; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS;

AGE FACTORS; AGED; CAPTOPRIL; CAUSE OF DEATH; CONFIDENCE INTERVALS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SURVIVAL ANALYSIS; TETRAZOLES; TIME FACTORS; VALINE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 79551499429     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfq194     Document Type: Article

References (24)

1. Benhorin J, Moss AJ, Oakes D. Prognostic significance of nonfatal myocardial rein-farction. Multicenter Diltiazem Postinfarction Trial Research Group. J Am Coll Cardiol 1990;15:253-258.
2. Kornowski R, Goldbourt U, Zion M, Mandelzweig L, Kaplinsky E, Levo Y, Behar S. Predictors and long-term prognostic significance of recurrent infarction in the year after a first myocardial infarction. SPRINT Study Group. Am J Cardiol 1993; 72:883-888. (Pubitemid 23298063)
3. Mueller HS, Forman SA, Menegus MA, Cohen LS, Knatterud GL, Braunwald E. Prognostic significance of nonfatal reinfarction during 3-year follow-up: results of the Thrombolysis in Myocardial Infarction (TIMI) phase II clinical trial. The TIMI Investigators. J Am Coll Cardiol 1995;26:900-907.
4. Cannon CP, Sharis PJ, Schweiger MJ, McCabe CH, Diver DJ, Shah PK, Sequeira RF, Greene RM, Perritt RL, Poole WK, Braunwald E. Prospective validation of a composite end point in thrombolytic trials of acute myocardial infarction (TIMI 4 and 5). Thrombosis In Myocardial Infarction. Am J Cardiol 1997;80:696-699.
5. Kavsak PA, MacRae AR, Lustig V, Bhargava R, Vandersluis R, Palomaki GE, Yerna MJ, Jaffe AS. The impact of the ESC/ACC redefinition of myocardial infarction and new sensitive troponin assays on the frequency of acute myocardial infarction. Am Heart J 2006;152:118-125.
6. Kontos MC, Fritz LM, Anderson FP, Tatum JL, Ornato JP, Jesse RL. Impact of the troponin standard on the prevalence of acute myocardial infarction. Am Heart J 2003;146:446-452.
7. Trevelyan J, Needham EWA, Smith SCH, Mattu RK. Impact of the recommendations for the redefinition of myocardial infarction on diagnosis and prognosis in an unselected United Kingdom cohort with suspected cardiac chest pain. Am J Cardiol 2004;93:817-821.
8. Pfeffer MA, McMurray J, Leizorovicz A, Maggioni AP, Rouleau JL, Van De Werf F, Henis M, Neuhart E, Gallo P, Edwards S. Valsartan in Acute Myocardial Infarction Trial (VALIANT): rationale and design. Am Heart J 2000;140:727-750.
9. Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van De Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM, the Valsartan in Acute Myocar-dial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-1906.
10. Ørn S, Cleland JGF, Romo M, Kjekshus J, Dickstein K, Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction, Am J Med, 2005, 118, 752-758.
11. Volpi A, De Vita C, Franzosi MG, Geraci E, Maggioni AP, Mauri F, Negri E, Sontoro E, Tavazzi L, Tognoni G. Predictors of nonfatal reinfarction in survivors of myocardial infarction after thrombolysis. Results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2) Data Base. J Am Coll Cardiol 1994;24:608-615.
12. Brener SJ, Ellis SG, Sapp SK, Betriu A, Granger CB, Burchenal JEB, Moliterno DJ, Califf RM, Topol EJ, GUSTO IIb and RAPPORT Investigators. Predictors of death and reinfarction at 30 days after primary angioplasty: The GUSTO Ilb and RAPPORT trials. Am Heart J 2000;139:476-481.
13. Dönges K, Schiele R, Gitt A, Wienbergen H, Schneider S, Zahn R, Grube R, Baumgertel B, Glunz HG, Senges J. Incidence, determinants, and clinical course of reinfarction in-hospital after index acute myocardial infarction (results from the pooled data of the maximal individual therapy in acute myocardial infarction [mitra], and the myocardial infarction registry [MIR]). Am J Cardiol 2001;87: 1039-1044.
14. Hudson MP, Granger CB, Topol EJ, Pieper KS, Armstrong PW, Barbash GI, Guerci AD, Vahanian A, Califf RM, Ohman EM. Early reinfarction after fibrinolysis: experience from the Global Utilization of Streptokinase and Tissue Plasminogen Activator (Alteplase) for Occluded Coronary Arteries (GUSTO I) and Global Use of Strategies To Open Occluded Coronary Arteries (GUSTO III) Trials. Circulation 2001;104:1229-1235.
15. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004;351: 1285-1295.
16. Inglis SC, McMurray JJV, Böhm M, Schaufelberger M, Van Veldhuisen DJ, Lindberg M, Dunselman P, Hjalmarson A, Kjekshus J, Waagstein F, Wedel H, Wikstrand J. Intermittent claudication as a predictor of outcome in patients with ischaemic systolic heart failure: analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure trial (CORONA). Eur J Heart Fail 2010;12:698-705.
17. Buch P, Rasmussen S, Gislason GH, Rasmussen JN, Kober L, Gadsboll N, Stender S, Madsen M, Torp-Pedersen C, Abildstrom SZ. Temporal decline in the prognostic impact of a recurrent acute myocardial infarction 1985 to 2002. Heart 2007;93:210-215.
18. Kernis SJ, Harjai KJ, Stone GW, Grines LL, Boura JA, Yerkey MW, O'Neill W, Grines CL. The incidence, predictors, and outcomes of early reinfarction after primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 2003;42: 1173-1177. (Pubitemid 37188336)
19. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous throm-bolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003;361:13-20.
20. Andersen HR, Nielsen TT, Rasmussen K, Thuesen L, Kelbaek H, Thayssen P, Abildgaard U, Pedersen F, Madsen JK, Grande P, Villadsen AB, Krusell LR, Haghfelt T, Lomholt P, Husted SE, Vigholt E, Kjaergard HK, Mortensen LS. A Comparison of Coronary Angioplasty with Fibrinolytic Therapy in Acute Myocar-dial Infarction. N Engl J Med 2003;349:733-742.
21. Gulliksson M, Wedel H, Koster M, Svardsudd K. Hazard function and secular trends in the risk of recurrent acute myocardial infarction: 30 years of follow-up of more than 775 000 incidents. Circ Cardiovasc Qual Outcomes 2009; 2:178-185.
22. Mehran R, Pocock SJ, Stone GW, Clayton TC, Dangas GD, Feit F, Manoukian SV, Nikolsky E, Lansky AJ, Kirtane A, White HD, Colombo A, Ware JH, Moses JW, Ohman EM. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur Heart J 2009;30:1457-1466.
23. Yeh RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med 2010;362: 2155-2165.
24. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, Van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933-989.